Eris Lifesciences Ltd (NSE:ERIS)
₹ 1042.9 11.1 (1.08%) Market Cap: 141.66 Bil Enterprise Value: 155.44 Bil PE Ratio: 36.17 PB Ratio: 5.48 GF Score: 97/100

Q3 2023 Eris Lifesciences Ltd Earnings Call Transcript

Jan 17, 2023 / 12:00PM GMT
Release Date Price: ₹651.8 (+0.50%)
Operator

Ladies and gentlemen, good day, and welcome to Eris Lifesciences Limited Q3 FY '23 Earnings Conference Call. We have with us on the call today, Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Executive Director and Chief Operating Officer.

(Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. V. Krishnakumar, Executive Director and Chief Operating Officer. Thank you, and over to you, sir.

Krishnakumar Vaidyanathan
Eris Lifesciences Limited - Executive Director & COO

Thank you. I'm Krishnakumar and I wish you all a very Happy New Year. Welcome to our earnings call for the third quarter of financial year '23. We've just announced the acquisition of 9 dermatology brands from Glenmark. This deal is in line with our stated intent of building a strong dermatology franchise. We started this process with the acquisition of Oaknet in May 2002 (sic) [2022].

The acquisition of the Glenmark brands will help consolidate our position further, especially in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot